Cassava Sciences reported $-11.73M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Abbott USD 2.43B 844M Mar/2026
Amgen USD 5.8B 1.25B Sep/2026
Biogen USD 450.8M 198.9M Jun/2026
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Eisai JPY 25.94B 8.21B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Geron USD -9.2M 13.03M Jun/2026
J&J USD 8.99B 721M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Novartis USD 8.62B 2.14B Sep/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.36B 350M Sep/2026
Roche Holding CHF 13.43B 744M Jun/2026